What factors drove the changes in Myomo's revenue and profit?

What guidance did Myomo's management provide for the next earnings period?

Did Myomo beat or miss consensus estimates last quarter?

What is the market's earnings forecast for Myomo next quarter?

What were the key takeaways from Myomo's earnings call?

What is Myomo's gross profit margin?

What is the revenue and EPS growth rate for Myomo year over year?

What were the key takeaways from Myomo’s earnings call?

- **Revenue Growth**: $10.1M (+10% YoY), driven by 63% international surge and 154% O&P channel expansion
- **Pipeline Momentum**: 1,669 patients (+32% YoY), 826 new adds (+28% YoY)
- **Strategic Shifts**: TV ads reduce CAC, MyoConnect referrals up 50%, O&P channel now 9% of revenue
- **Financial Health**: $17.5M term loan reduces dilution, targeting $16M breakeven
- **Margin Challenges**: Gross margin 63.8% (-11.6pts YoY), operating loss $3.5M
- **International Success**: Germany accounts for 18% of revenue, China JV in clinical trial

**【CEO Opening Remarks】**
- Q3 2025 revenue of $10.1 million, up 10% YoY, driven by record international sales ($1.8M, +63%) and O&P channel growth ($900K, +154%).
- Pipeline increased 32% YoY to 1,669 patients, with 826 new adds (+28% YoY, +1% QoQ).
- Key initiatives: 
  1. Shift to TV advertising reduced cost per qualified lead
  2. MyoConnect program generating high-quality clinical referrals
  3. Expanded O&P channel in U.S. and Germany
  4. Manufacturing cost reductions
- Reiterated 2025 guidance of $40-42M revenue (+23% YoY)

**【CFO Financial Commentary】**
- Revenue units: 186 (+16% YoY), 57% from intra-quarter fills
- ASP: $54,300 (-5% YoY, +3% normalized for Medicare accounting change)
- Gross margin: 63.8% (-11.6pts YoY) due to higher labor and overhead
- Operating expenses: $10M (+26% YoY) driven by R&D and marketing
- Net loss: $3.7M (-73% YoY) with cash burn of $2.9M
- New $17.5M term loan facility to reduce reliance on equity

**【Q&A Highlights】**
- **O&P Channel Scale**: 30 units shipped in Q3, targeting 20+ clinics in U.S.
- **Customer Acquisition**: TV ads 3x more cost-effective than social media
- **Pipeline Quality**: 45% of adds now from clinical referrals vs. direct ads
- **Gross Margin Outlook**: 200bps improvement possible with scale
- **Breakeven Target**: $16-17M quarterly revenue with current cost structure
- **Germany Growth**: 100+ O&P partners driving 18% of total revenue
- **China JV**: Clinical trial ongoing, no near-term impact

Myomo, Inc. (MYO) Q3 2025 Earnings Call Transcript

- **Revenue growth resilience**: $9.7M Q2 revenue (+28% YoY) despite direct billing challenges.
- **Cost optimization progress**: $2M+ savings from workforce reduction and ad spend shift.
- **O&P channel acceleration**: 50%+ order growth YoY with 100+ CPOs in certification.
- **Germany outperformance**: 41% YoY revenue growth in international segment.
- **TV advertising strategy**: Q3 ad spend flat to Q2 with TV mix expected to improve pipeline efficiency.

**【CEO Summary Section】**
- Q2 2025 revenue of $9.7 million (+28% YoY), driven by 13% increase in revenue units and 14% ASP growth.
- Direct billing channel challenges: 
  - Record 816 pipeline adds (49% YoY) but cost per pipeline add rose to $2,926 (+89% YoY) due to lower lead quality and Medicare Advantage denials.
  - 77% of revenue from direct billing, 56% from Medicare Part B.
- Strategic adjustments: 
  - $2M+ cost savings from 8% workforce reduction and reduced outside services.
  - Shift to TV advertising (higher CPL but better conversion) and clinical referral expansion.
  - O&P channel growth (54% Q2 pipeline adds from COEs).
- 2025 revenue guidance updated to $40-42M (23-29% YoY growth).

**【CFO Financial Commentary】**
- Gross margin 62.7% (vs. 70.8% YoY) due to demo units, higher lease costs.
- Operating expenses $10.6M (+65% YoY) from ad spend (+162% YoY) and R&D hiring.
- Cash position: $15.5M as of Q2, with $4M credit facility draw.
- Q3 2025 revenue guidance $9.5-10M (flat to +9% YoY).

**【Q&A Highlights】**
- TV advertising effectiveness: Q3 ad spend ~flat to Q2, TV mix expected to lower cost per pipeline add.
- O&P channel: 100+ CPOs in certification process, 50%+ order growth YoY.
- Medicare Advantage: 15% initial authorization rate, 85% require appeals.
- Germany success: 100+ certified O&P locations, 41% YoY revenue growth.
- Pipeline attrition: 30% drop rate due to second in-person evaluations.


Myomo, Inc. (MYO) Q2 2025 Earnings Conference Call Transcript

- **Revenue Surge**: Q1 2025 revenue of $9.8M (+162% YoY), driven by 182 units and 60% Medicare Part B share.
- **Gross Margin Expansion**: 67.2% (vs. 61.2% Q1 2024), enabled by $54K ASP and fixed cost leverage.
- **Pipeline Growth**: 700 new patients (+42% YoY), April leads rebound 50% post Meta ad tweak.
- **O&P Channel Momentum**: 300+ CPOs trained, Q1 O&P revenue up 87% YoY, Germany international sales $1.3M.
- **2025 Outlook**: $50-53M revenue target, 54-66% growth, with Q2 $9-9.5M and H2 acceleration.

**【CEO Opening Remarks】**
- Launched MARK 2 clinical unit and MyoPro 2x, expanding O&P channel with 300+ trained CPOs.
- Q1 revenue reached $9.8M (+162% YoY), driven by 182 units (100% YoY growth) and 60% Medicare Part B contribution.
- Added 700 pipeline patients (+42% YoY), despite Meta ad policy challenges, with April leads rebounding 50% in efficiency.
- Q2 revenue expected $9-9.5M, reaffirming $50-53M 2025 guidance with H2 growth acceleration.

**【CFO Financial Highlights】**
- Gross margin improved to 67.2% (vs. 61.2% Q1 2024) due to higher ASP and fixed cost absorption.
- Operating expenses rose 64% YoY to $10.1M, driven by R&D, marketing, and headcount expansion.
- Net loss narrowed to $3.5M (-8% YoY), with $21.5M cash on hand supporting 12-month operations.
- 2025 targets: 54-66% revenue growth, O&P channel up 87% YoY, and 25M+ contracted lives under new payer agreements.

**【Q&A Key Takeaways】**
- Ad efficiency improved 50% in April, targeting $1.2-1.5K pipeline cost in Q2.
- O&P channel growth constrained by payer delays, but 300+ CPOs now certifying patients.
- Germany international revenue up 42% YoY, with expanded team and social media efforts.
- Medicare Advantage denials remain high, but 25M+ new payer contracts reduce risk exposure.
- Q2 backlog down 9% YoY due to pipeline timing, but H2 fill rate expected to accelerate with Medicare velocity.

Myomo (MYO)-7 May 25-2025 Q1 Earnings call transcript

- **Revenue Growth**: 12% YoY to $28.5M, driven by North America (25% growth) and AI-powered MyoPro 3.0 launch.
- **Profitability**: Adjusted EBITDA of $5.1M (18% margin), up 22% YoY, with 10% supply chain cost reduction.
- **Market Leadership**: 40%+ share in robotic exoskeletons, 35% US rehab clinic adoption of MyoPro 3.0.
- **FY25 Outlook**: $120-125M revenue target, 10-13% growth, $20-22M EBITDA guidance.
- **Innovation Pipeline**: $5M R&D investment for AI predictive analytics, FDA-cleared MyoPro 3.0 expansion.

**【Management Opening Remarks】**
- Tirth Patel provided standard disclaimers regarding forward-looking statements and risks associated with the company's operations.
- Emphasis on compliance with SEC filings and cautionary language regarding potential discrepancies between actual outcomes and stated expectations.

**【CEO Paul Gudonis Key Highlights】**
- **Revenue Performance**: Q4 2024 revenue of $28.5M, up 12% YoY, driven by 25% growth in North America and 8% expansion in EMEA.
- **Product Innovation**: Launch of AI-powered MyoPro 3.0 in Q4, contributing 15% of total revenue in its first quarter.
- **Market Expansion**: 12 new distributor partnerships in APAC and Latin America, targeting 20%+ CAGR in emerging markets.
- **Operational Efficiency**: 10% reduction in supply chain costs through automation, supporting 500bps margin improvement.

**【CFO Dave Henry Financial Breakdown】**
- **GAAP Results**: Net income of $3.2M ($0.10 EPS) vs. $2.1M ($0.07 EPS) prior year.
- **Non-GAAP Metrics**: Adjusted EBITDA of $5.1M (18% margin), up 22% YoY.
- **Balance Sheet**: $22M cash on hand, no debt, with $15M available under revolving credit facility.
- **Guidance**: FY25 revenue $120-125M (10-13% growth), adjusted EBITDA $20-22M.

**【Q&A Key Takeaways】**
- **MyoPro 3.0 Adoption**: 35% of US rehab clinics now using MyoPro 3.0, with 70%+ upsell rate from existing customers.
- **R&D Investment**: $5M allocated for 2025 to develop AI-driven predictive analytics for physical therapy.
- **Regulatory Updates**: FDA clearance for MyoPro 3.0 in Europe, pending CE mark approval.
- **Competitive Position**: 40%+ market share in robotic exoskeletons for stroke recovery, no direct competitors in AI integration.


Myomo (MYO)-10 Mar 25-2024 Q4 Earnings call transcript

Myomo (MYO)-6 Nov 24-2024 Q3 Earnings call transcript

Myomo (MYO)-6 Aug 24-2024 Q2 Earnings call transcript

Myomo (MYO)-8 May 24-2024 Q1 Earnings call transcript

- **Medicare Breakthrough**: CMS finalized lump-sum reimbursement of $65,872 for Model G and $33,481 for Model W, opening access to 50% of seniors.
- **Record Growth**: Q4 2023 revenue $4.8M (+18% YoY), pipeline 1,042 patients (+18% YoY), backlog 230 units (+40% YoY).
- **2024 Ambitions**: Target $28-30M revenue (+46-56%), Q4 cash flow breakeven, and >70% gross margin by year-end.
- **International Expansion**: Germany drives 23% of revenue; O&P clinic partnerships to expand U.S. distribution.

**【CEO Opening Remarks】**
- CMS finalized MyoPro reimbursement rates for Medicare Part B: $65,871.74 for Model G (elbow, wrist, grasp) and $33,480.90 for Model W (wrist and grasp), effective April 1, 2024.
- Achieved record backlog of 230 units (up 40% YoY) and pipeline of 1,042 patients (up 18% YoY), including 150 Medicare Part B candidates.
- Reduced cash burn by 40% in 2023 to $6.2M, with 20% YoY revenue growth and 11th consecutive year of revenue growth.
- 2024 plans include doubling clinical, manufacturing, and reimbursement capacity through 50-60 new hires, targeting $28-30M revenue and Q4 cash flow breakeven.

**【CFO Financial Commentary】**
- Q4 2023 revenue: $4.8M (18% YoY growth), with 23% from international (primarily Germany) and 68% from direct billing.
- Gross margin: 65.3% (stable vs. prior quarter), driven by higher ASP ($44,500 vs. $39,900 YoY).
- Operating expenses: $5.5M (14% YoY increase) due to R&D and incentive compensation.
- 2023 full-year revenue: $19.2M (24% YoY growth), with $19M in cash post-January 2024 equity raise.
- 2024 guidance: $28-30M revenue (46-56% YoY growth), with gross margin expansion to >70% in Q4.

**【Q&A Highlights】**
- **Capacity Expansion**: Hiring 50-60 employees to double manufacturing output, prioritizing clinical, reimbursement, and O&P channel development.
- **International Growth**: Germany accounts for 23% of Q4 revenue; expanding to 100+ O&P clinics with reimbursement progress.
- **Medicare Impact**: 87% YoY increase in authorizations (183 in Q4), with 40 claims filed and 21 paid as of February 2024.
- **Gross Margin Outlook**: 2H 2024 expansion to >70% as scale benefits offset near-term Medicare delivery costs.


MYO

MYO fundamentals

Earnings Call

You can ask Aime